Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

BUY
$15.36 - $27.51 $4.45 Million - $7.97 Million
289,810 New
289,810 $7.18 Million
Q1 2022

May 13, 2022

SELL
$22.22 - $39.12 $1.63 Million - $2.88 Million
-73,505 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$18.38 - $40.5 $1.35 Million - $2.98 Million
73,505 New
73,505 $2.68 Million
Q2 2021

Aug 16, 2021

SELL
$9.59 - $50.88 $38,599 - $204,792
-4,025 Closed
0 $0
Q1 2021

May 12, 2021

SELL
$49.53 - $68.4 $1,436 - $1,983
-29 Reduced 0.72%
4,025 $206,000
Q4 2020

Feb 16, 2021

BUY
$47.25 - $65.16 $155,452 - $214,376
3,290 Added 430.63%
4,054 $251,000
Q3 2020

Aug 05, 2021

SELL
$46.35 - $61.69 $143,963 - $191,609
-3,106 Reduced 80.26%
764 $42,000
Q3 2020

Nov 16, 2020

BUY
$46.35 - $61.69 $13,905 - $18,507
300 Added 8.4%
3,870 $212,000
Q2 2020

Aug 12, 2020

SELL
$38.58 - $65.07 $493,438 - $832,245
-12,790 Reduced 78.18%
3,570 $205,000
Q2 2019

Aug 08, 2019

SELL
$8.31 - $14.85 $47,200 - $84,348
-5,680 Reduced 25.77%
16,360 $0
Q1 2019

May 15, 2019

BUY
$10.01 - $13.89 $116,716 - $161,957
11,660 Added 112.33%
22,040 $0
Q2 2018

Aug 13, 2018

BUY
$10.62 - $13.98 $110,235 - $145,112
10,380 New
10,380 $0

Others Institutions Holding CCXI

About ChemoCentryx, Inc.


  • Ticker CCXI
  • Exchange NASDAQ
  • Shares Outstandng 71,919,696
  • Market Cap $3.68M
  • Description
  • ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...
More about CCXI
Track This Portfolio

Track Prudential Financial Inc Portfolio

Follow Prudential Financial Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prudential Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Prudential Financial Inc with notifications on news.